Walk into a typical OB-GYN appointment with questions about hormone therapy and you may walk out with more confusion than you started with. That is the reality Tara Nowakhtar, DO, sees playing out across her specialty, and she traces much of it back to a single event: the Women's Health Initiative, a large federal study whose 2002 results triggered a wave of alarm about breast cancer and heart disease risks from hormone therapy. The alarm, she argues, was disproportionate to the actual data, and the consequences have outlasted the headlines by decades.
Her first move with any patient is to address that legacy directly. "I start by clearing the air on the overblown WHI data, then anchor the conversation in absolute, not relative, risk," Nowakhtar said. The distinction matters enormously. A relative risk figure can make a small absolute increase sound catastrophic, and in 2002, that framing shaped clinical practice in ways that are still felt today. Clinicians who trained during and after that period absorbed a particular caution, and patients who were premenopausal then arrived at menopause already primed to fear treatment. The result, as Nowakhtar describes it, is a generation on both sides of the exam table without a clear picture of what the evidence actually shows.
Her own training left similar gaps. She learned to recognize the textbook presentation: hot flashes, night sweats, insomnia. What her education did not give her was a framework for treatment, or for recognizing perimenopause when it arrives disguised as something else entirely. "Connecting those dots was challenging, and a fragmented healthcare system is certainly a contributing factor," she said. The clinical knowledge she now draws on came largely from experience, from adjusting medications when patients were not improving and learning, as she put it, that "a little tweaking can go a long way."
When Nowakhtar does evaluate a patient for hormone therapy, the assessment is specific to that individual. She considers timing, formulation, and route of administration, not as a checklist but as variables that interact with a patient's particular history. She reviews Tyrer-Cuzick breast cancer risk estimates drawn from personal and family history, alongside lipid panels including LDL and Lp(a) and a broader cardiovascular risk picture. Prior breast cancer, a history of clots, or existing heart disease each change her answer in ways no general guideline can fully anticipate.
The structure of a typical clinical visit makes that kind of individualized assessment nearly impossible. In 60 to 90 minute appointments, Nowakhtar said she can trace how a patient's symptoms have shifted month to month and year to year, walk through the risks, benefits, and alternatives for every option, and still have time to address lifestyle factors she considers equally important to long-term health. "My patient leaves her visit with a plan built around her, not the clock," she said. The contrast with a rushed standard visit is not incidental. It is the whole point. A short appointment does not just limit what gets discussed; it shapes what questions a patient even thinks to ask, and what she believes is possible.
The patients walking into practices like Nowakhtar's today grew up in the shadow of that 2002 alarm. Some of their clinicians did too. The question that lingers is how many women in the years between never got the conversation at all.
